The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma.
Francis AM, Sepesi B, Correa AM, Blum MA, Erasmus JJ, Lee JH, Maru DM, Mehran RJ, Rice DC, Roth JA, Vaporciyan AA, Walsh GL, Welsh JW, Swisher SG, Hofstetter WL; University of Texas MD Anderson Esophageal Cancer Group.
Francis AM, et al. Among authors: roth ja.
Ann Surg. 2013 Sep;258(3):500-7. doi: 10.1097/SLA.0b013e3182a196f4.
Ann Surg. 2013.
PMID: 24022442